OxyPrem uses harmless light (more on NIRS) to determine absolute haemoglobin oxygen saturation in any human tissue.
OxyPrem is a reusable device which offers better clinical care due to its high quality, while substantially reducing waste.
With its excellent performance in repeated placement and its high reading certainty, OxyPrem sets new standards in precision.
High-quality components and advanced algorithms allow for superior reliability, especially in low-perfusion environments.
Several easy ways to attach OxyPrem to the patient (bandages, CPAP, ...).
Simple disinfection using alcoholic wipes.
OxyPrem's glue-free fixation preserves the skin, and its very soft silicone hull is highly comfortable to wear.
OxyPrem can be used in any patient at the risk of hypoxia and on any body part which is at least 30 mm thick.
Since OxyPrem is reusable, costs are reduced drastically when used routinely or over longer time periods.
Links to publications on OxyPrem and its predecessor devices:
1
,
2
,
3
,
4
August 2019
The OxyPrem team has successfully completed Venture Kick stage 3. After one year, the Venture Kick journey has come to an end and OxyPrem will receive an additional CHF 100'000.-- in funding.
The official announcement is here.
February 2019
Wyss Zurich is a joint accelerator by University of Zurich and ETH Zurich, made possible by a generous donation by philantropist Dr. h.c. mult. Hansjörg Wyss.
Please visit our profile page here.
December 2018
The UZH Faculty of Medicine has received a considerable donation by Uniscientia Foundation. It will be used to support OxyPrem.
Thank you for the encouragement from the entire team!
November 2018
OxyPrem advances to Venture Kick stage II.
Thanks to the jury for the exciting session and the interesting questions and good feedback.
The official announcement is here.
September 2018
OxyPrem has reached the semifinals in the pitching battle of Startup Days 2018.
This puts OxyPrem on par with the English national team.
September 2018
OxyPrem has successfully achieved participation in the VentureLab AIT India programme.
We will take part in a one-week visit to India in December to meet clinicians and industry partners.
August 2018
We are now part of Switzerland's well known Venture Kick programme.
Our team successfully completed the stage I pitch and will soon be heading for the "kickers camp" to prepare for stage II and exchange ideas with other founders.
The official announcement is here.
May 2018
The UZH Annual Media Conference has brought about some press coverage:
For example
here,
here,
here,
here,
here, and
here.
A big thank you to all the journalists for the interesting questions and the good reporting!
April 2018
The OxyPrem team is heading for Stuttgart to establish production partnerships.
Please contact us to get in touch at the event.
Find additional information here:
Medtec Europe, Stuttgart 2018
February 2018
The OxyPrem team has started a collaboration with Zurich-based Therapy Development Accelerator (TDA).
The TDA expert team offers a wide range of knowledge, infrastructure, and services to push partnering projects forward.
Visit the TDA website for more information.
February 2018
Project OxyPrem is now part of the UZH BioEntrepreneur Fellowship program by the University of Zurich.
Find additional information here:
Fellowship information
List of Fellows
Aug 2017
OxyPrem will be part of this year's
Rising Stars Start-Up Showcase
of the Sachs MedTech & Digital Health Forum in
Basel, Switzerland on Sep 25th, 2017.
Find additional information here:
5th Annual MedTech & Digital Health Forum
Technology
+49 160 929 339 76
kleiser@oxyprem.com
Business Development
+41 76 263 87 31
nitsch@oxyprem.com
OxyPrem AG
c/o Universität Zürich
Klinik für Neonatologie
Frauenklinikstrasse 10
8091 Zürich (Switzerland)